Skip to content
HowShorted

PETMED EXPRESS INC short interest in 2023

In 2023, PETMED EXPRESS INC's disclosed short interest ran from 19.04% of shares outstanding on 13 Jan 2023 to 16.78% on 29 Dec 2023, a change of -2.26 percentage points. The year's high was 25.61% on 15 Jun 2023 and its low 12.95% on 15 Nov 2023, averaging 18.60% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.64 days on 15 May 2023. Full history: PETMED EXPRESS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for PETMED EXPRESS INC in 2023

2023 in figures

Start of year
19.04% (13 Jan 2023)
End of year
16.78% (29 Dec 2023)
Change
-2.26 pp
High
25.61% (15 Jun 2023)
Low
12.95% (15 Nov 2023)
Average
18.60%
Highest days to cover
15.64 (15 May 2023)
SEC filings marked
9

Every report in 2023

PETMED EXPRESS INC short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202319.04%14.99
31 Jan 202321.65%10.48
15 Feb 202322.93%9.75results (8-K), 10-Q filed
28 Feb 202319.94%9.30
15 Mar 202322.71%11.44
31 Mar 202321.85%7.61
14 Apr 202324.45%15.28
28 Apr 202322.24%14.93
15 May 202322.29%15.64
31 May 202322.36%9.55results (8-K), 10-K filed, results (8-K)
15 Jun 202325.61%8.39
30 Jun 202318.56%3.55
14 Jul 202317.15%8.46
31 Jul 202315.52%9.30results (8-K)
15 Aug 202315.55%5.9910-Q filed
31 Aug 202315.17%8.44
15 Sep 202316.85%6.98
29 Sep 202313.29%10.02
13 Oct 202313.07%6.81
31 Oct 202316.60%4.71results (8-K), 10-Q filed
15 Nov 202312.95%4.59
30 Nov 202314.39%4.96
15 Dec 202315.49%7.27
29 Dec 202316.78%11.10

See also: PETMED EXPRESS INC's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.